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INTRODUCTION
There are three well-accepted management strategies
for patients with non-investigated dyspepsia. These are
the early endoscopy for all, empiric antisecretory
therapy, or the Helicobacter pylori test and treat strategy,
with benefits and limitations to each of these methods.
Although early endoscopy provides a precise diagnosis
that guides treatment, its widespread use is limited by its
cost (at least in countries such as the USA), availability,
and risk for complications that is largely related to the
need for conscious sedation. Therefore, it is generally
reserved for those patients with onset of dyspepsia
symptom after aged 45–50 years, those of all ages with
concurrent alarm symptoms, and those who fail to
respond to H. pylori test and treat strategies or empiric
antisecretory therapy.
The test and treat strategy has the advantage of not
requiring endoscopy, being less costly than endoscopy,
and offers the potential for curative treatment in those
found to be infected with H. pylori. Its clinical utility is
probably greatest in younger patients without alarm
symptoms in geographic regions where H. pylori
prevalence remains robust but gastric cancer preval-
ence is low. The contribution of H. pylori infection to
dyspeptic symptoms appears to vary based upon
geographic and demographic factors.1,2 A recent update
of the Cochrane systematic review of H. pylori eradica-
tion therapy in patients with functional dyspepsia found
a small but significant benefit associated with cure of
the infection: 37% mean response rate in the active
treatment group compared with 29% in those treated
with placebo or a short course of PPI therapy.3
Empiric antisecretory therapy is a widely used, cost-
effective, safe management strategy in those with
dyspepsia. In a recent publication, two double-blind,
randomized, placebo-controlled trials involving 921
patients with functional dyspepsia found that treatment
with a proton-pump inhibitor (PPI; lansoprazole 15 mg
or 30 mg once daily for 8 weeks) produced significantly
(P < 0.001) greater mean reductions in the percentage
of days with upper abdominal discomfort and, as
illustrated in Figure 1, significantly greater number of
patients with complete symptom resolution compared
with placebo-treated patients.4 The finding of PPIs being
superior to placebo in relieving symptoms is similar to
that of a recently updated Cochrane meta-analysis of
pharmacological interventions for functional dyspepsia.5
The major disadvantage to this strategy is that it may, on
rare occasions, mask serious disease and postpone timely
investigation or subject patients with a curable disease
(i.e. H. pylori-related ulcer disease) to long-term phar-
macological therapy. A recent study reported that
response to PPI treatment in functional dyspepsia was
most reliable in patients with dyspepsia of short-duration
(few days of heartburn during the first week and a
history of symptoms for <3 months); low scores for
bloating, epigastric pain and diarrhoea;6 and in young
patients with dyspepsia and no alarm symptoms.
Workshop Consensus on Clinical Management Issues
The prevalence of H. pylori infection and its contribution to
dyspepsia may vary across different geographic regions.
What are the current recommendations for testing for
H. pylori infection among patients presenting with dyspep-
sia? Unfortunately, there is no general consensus or
recommendations for H. pylori testing among patients
with dyspepsia. Factors that influence patient
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management strategies include the prevalence of H. py-
lori and the cost and effectiveness of diagnostic testing
and treatment. For example, in Asia where the preval-
ence of H. pylori and gastric cancer are high and the
costs of endoscopy are low, patients with dyspepsia
often undergo endoscopy with H. pylori testing early in
the management algorithm. On the contrary, in the
USA and Europe where H. pylori prevalence is relatively
low and the costs of endoscopy are relatively high,
affected patients more often are treated empirically with
antisecretory drugs. Most often patients with dyspepsia
in a low H. pylori prevalence region have functional
dyspepsia or an acid-related disorder such as reflux
disease. The use of empiric PPI treatment is a more
rational and cost-effective approach than the test and
treat strategy or immediate endoscopy. Endoscopy
should be performed in patients of any age with alarm
symptoms (i.e. weight loss, gastrointestinal blood loss,
anaemia, vomiting, severe or progressive symptoms),
those >45–50 years of age with new onset symptoms,
as well as for those who fail to respond to antisecretory
therapy or the test and treat strategy. The cost-
effectiveness and effect on clinical outcomes of combi-
ning empiric antisecretory therapy and the test and
treat strategy before proceeding to endoscopy deserves
further study. A recent decision analysis model found
that such an approach before endoscopy might be more
cost-effective than employing either strategy alone.7
Is empiric PPI treatment a safe, rational and appropriate
approach for patients with dyspepsia and without alarm
features’? More than 99% of workshop participants
agreed (75% strongly and 24% with some reservation)
that empiric PPIs are a safe, rational and appropriate
strategy for the management of patients with dyspepsia
and without alarm features.
Is PPI treatment a preferred first-line approach for patients
with NSAID-associated dyspepsia, assuming the absence of
alarm features’? About 59% agreed with reservations
(e.g. age of the patient) and 29% strongly agreed that PPI
therapy is a preferred first-line approach for patients with
non-steroidal anti-inflammatory drug (NSAID)-associ-
ated dyspepsia. About 12% either disagreed with reser-
vation (6%) or strongly disagreed (6%)with this strategy.
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*P < 0.05 vs.placebo
Figure 1. Placebo-controlled trials of
lansoprazole in functional dyspepsia.
Two identically designed trials found that
treatment with lansoprazole 15 mg or
30 mg once daily produced complete
symptom relief in significantly higher
percentages of patients compared with
placebo. Adapted from Peura et al.4
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